# AbbVie Revenue Rises on Strength in Immunology, Neuroscience

> **Newsylist Open Intelligence Dossier** · First detected: 2026-10-31 21:29 UTC · Category: Business · Sources: 3 · Current Velocity: 1.3

## Key People, Organizations & Locations
Immunology, Strength, Revenue, Rises, AbbVie, Neuroscience

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| KTVB | AbbVie: Q3 Earnings Snapshot | 2026-10-30 12:00 | [Source Link](https://news.google.com/rss/articles/CBMiwwFBVV95cUxNNk9HalFkWmZJS0tNY3EtdHdRMENjRkZuZnVEWFdJS2ZpdGFfRnhhSUxYR2xKazVRY2N3ZmpkcVV2b051eW1KVUVXbnZ3UVVPZzEyRmFaS3VYcXhzeFV4YW96R0Z6WU9aN3d5ODRqd3FwY2xHY3JDalZZNkdBdEcxUC1qVTRGc2R4amcwb1UwVHN1SFhQR2JpYWQtTkpIT2Y5OUxmS2VhQlJyZXR0Xy1aampFU0hXZ09JWXlQWE1LbUxrWjA?oc=5) |
| Yahoo Finance | AbbVie (NYSE:ABBV) posts Q3 2026 sales in line with estimates | 2026-10-30 12:00 | [Source Link](https://news.google.com/rss/articles/CBMijwFBVV95cUxOeE1UQ3VMVkN5RWxuZjVYQXl4M2tPZG5sVTlkNTNLazZzOElhcS1aTDgwek9UNjVYTm1MVU9IYXZreHpqcFBKVHV6WGJFc1JKWnRhQ1hIME5GeU9ORnNjaVBsdEZFVS1MZDd5SHZSa2ZUczNQR2RpcjA4dkY3b1F0WlZpanJsSFg3NUxwNnl1aw?oc=5) |
| The Motley Fool | Is AbbVie a Buy After Its Latest Earnings Report? | 2026-10-30 12:00 | [Source Link](https://news.google.com/rss/articles/CBMilgFBVV95cUxPNmlmczk2WklQZ09HSEJNeEtBLXRocE1CU3diRmFEbi1wMFRBb0VOTVhTakNqS0s2djF3VFVUa2RPdkQ4MGVYMUZlUlVlXzFfUy1FMUpJQ0N5ZVBQbXk0RVJrNDZMbWxmN1dRLW5mWFpyVTdmT3p4d0pUTUVoaWdFdjd5TGhnV1ZSTThycGw4ZVNnYnZib1E?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-10-31/abbvie-revenue-rises-on-strength-in-immunology-neuroscience*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*
